info@nemooai.com

  Lucerne, Switzerland

GET A QUOTE

Next Generation Immuno Oncology (IO)

Uplifting IO cancer therapies to new spheres of efficacy ©

We are an immuno oncology (IO) company focused on developing breakthrough, most effective cancer treatments and related, breakthrough combinations (AI driven)

We are an EDC – an ethics driven company

We respect the role of capital and their active carrying of risks and upsides. We operate in a lean (AI driven), costs and risks reduced way

29

Years Of leading Scientific Research at University Hospitals worldwide

Dual MoA

Dual Mechanism of Action
to enter and kill malignant cells in various cancer types

17+

Identified cancer types or combinations for enhanced cancer therapies

435+

Man Years of Work for existing dual-technology platform (pre AI inclusion)

INTRODUCTION to AMEDIOO Health EDC

“We work where we work best.”

We own an independent and thorough understanding of our technologies and apply AI supported intelligence in immunology to transform various sectors of today’s cancer care to move them closer to “cure” (CR)

various tissues & cancer types

high medical need & lack of options (EDC)

major cancer types with improvements

Ambition is “cure” (CR/R) for most patients

27

YEARS

OF EXPERIENCE

MORE ABOUT US
“TOWARDS CURE” (CR) FOR MOST PATIENTS

Targeting far higher levels of efficacy

We stay very disciplined in our thinking and assumptions about what our significant, expected contributions can be – we re-evaluate and learn all the time. We use AI all the way. We reflect, decide from data (AI), scientific, medical and risk perspectives – and go for it

CANCER TYPE & “GAP”
We identify the gaps we can close best with our platform, technology. We like complements. We aim at far higher efficacy to get to or closer to cure (CR/R)
BIOENGINEERING & IP
We define the product (science, IP), model medical rationale over 10 years. We use all existing data (AI) and complement with tox studies if needed for IND and EMA and FDA
CLINICAL & TIME TO MARKET
We do the communication and financing, consult with EMA and FDA. We run (AI) clinical at lowest costs (adaptive). We prepare 18-24 months ahead of launches or exit
VIEW MORE PROJECTS
EDC – Ethics Driven Companies

We provide transparency, 
reviews & financial updates

As part of EDC companies, we were developed by NEMOO AI Value Builders EDC AG. We continue to benefit from their support and coaching, their structure, networks and governance. We jointly develop our projects, people, teams, ultimately our breakthrough products and add simple AI solutions for doctors. We sit together for future growth opportunities, manifold and often.

Best Experience

Our team is very solid, science, development, medical, launches and finance

Capital

We love to partner with investors and to create more value – together

For Further Information:

info@nemooai.com

NEMOO AI Value Builders AG is the founding partner and supporting us on corporate matters and finance.

And we all love to hear from you.

LEADERSHIP & GOVERNANCE

Experienced Team

The core team consists of a variety of backgrounds and skills, deep practical and operational experience in drug development (Parexel), pharmaceuticals (Roche, Biogen, AstraZeneca) and biotechnology (Amgen, Biogen), manufacturing (Lonza), scientific & clinical development (NovoNordisk, Roche, Parexel), corporate finance (SP, Merck) and general management (Roche, AZ, Biogen, Cubist, Sobi)

VIEW ALL MEMBER

Stay connected …

Updates & News:

We are posting updates, decisions or relevant news from time to time for investors, financial communities or employees – to foster identity and motivate (EDC)